Who are Repertoire Immune Medicines's investors?

Repertoire Immune Medicines's investors include Flagship Pioneering, SoftBank Vision Fund, JDRF T1D Fund.

Repertoire Immune Medicines

Founded 2020 · 84 employees on LinkedIn · 3 known investors

Repertoire's Decode platform focuses on mapping the immune synapse — the interactions between T cell receptors, epitopes, and HLA molecules — to support the development of medicines targeting cancer and other diseases. It operates in immunology-based drug discovery and therapeutics.

AI & Machine Learning Biotech Deep Tech Digital Health Healthtech

Founders & leadership

Torben Straight NisseninChief Executive OfficerExecutive Officer, Director at Rubius Therapeutics

Anthony CoyleinPresident, Research and Development

Robert AndtbackainChief Medical Officer

John DelyaniinChief Business Officer

Jan KisielowinChief Scientific Officer, Repertoire Immune Medicines (Switzerland) Ltd.

Investors · 3

Flagship PioneeringCambridge · $500K – $10M

SoftBank Vision FundLondon

JDRF T1D FundreportedBoston

Founder mafia

2 people who came through Repertoire Immune Medicines went on to found or lead other companies.

Noubar AfeyanBoard Member and Co-FounderFounded ProFound Therapeutics +12 Lovisa AfzeliusSenior Vice PresidentFounded AllTrna +2

In the news

Repertoire Immune Medicines Raises Investment from JDRF T1D Fundfinsmes.com · Mar 2020

Frequently asked questions

What does Repertoire Immune Medicines do?: Repertoire's Decode platform focuses on mapping the immune synapse — the interactions between T cell receptors, epitopes, and HLA molecules — to support the development of medicines targeting cancer and other diseases. It operates in immunology-based drug discovery and therapeutics.
Who are Repertoire Immune Medicines's investors?: Repertoire Immune Medicines's investors include Flagship Pioneering, SoftBank Vision Fund, JDRF T1D Fund.